Ranbaxy to provide generics in Germany under deal with AOK
This article was originally published in Scrip
Basics, a 100% subsidiary of Ranbaxy Laboratories, is to provide medicines in Germany following an agreement with AOK Baden-Wurttemberg. The agreement, which runs for two years, comes into effect on June 1st and includes Ranbaxy's cefaclor Basics (exclusive for all 15 AOK regional associations and five zones) and tamsulosin Basics (exclusive for 13 AOK regional associations and four zones ,with the exception of AOK Rhineland/Hamburg and AOK Westfalen Lippe zone). AOK is Germany's biggest health insurance group and its subscribers comprise nearly 24 million people.
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.